8-K: Seer Reports Q1 2026 Results, Reaffirms Guidance

Seer, Inc. announced first quarter 2026 financial results, reporting $2.8 million in revenue, a 34% decrease year-over-year, while reaffirming its full-year revenue outlook.

Summary

• Seer, Inc. reported $2.8 million in revenue for the first quarter of 2026, a 34% decrease compared to the same period in 2025, attributed to a challenging academic funding environment and competitive pressures.
• The company achieved $2.1 million in product revenue and $596 thousand in service revenue.
• Gross profit was $982 thousand, with a gross margin of 35%.
• Operating expenses decreased by 20% to $18.2 million, driven by lower employee compensation costs.
• The net loss for the quarter was $16.8 million, an improvement from $19.9 million in the prior year period.
• Free cash flow was approximately negative $15.7 million.
• Seer ended the quarter with approximately $220 million in cash, cash equivalents, and investments.
• The company reaffirmed its full-year 2026 revenue guidance of $16 million to $18 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment score due to the significant year-over-year revenue decline, despite reaffirming guidance and highlighting positive strategic developments.

Positives

• Secured a collaboration with Precision Health Research, Singapore for a large-scale proteomics study.
• Strengthened the leadership team with the appointment of Anthony (Tony) Bazarko as Chief Commercial Officer.
• Successfully defended and reinforced Seer's intellectual property position.
• Repurchased approximately 1.5 million Class A common shares.
• Ended the quarter with approximately $220 million in cash, cash equivalents, and investments.
• Doubled independent publications year-over-year to 84, accelerating third-party validation.

Negatives

• Revenue decreased by 34% to $2.8 million for the first quarter of 2026 compared to the prior year period.
• The decrease in revenue was primarily due to the continued depressed academic funding environment and competitive activity.
• Net loss was $16.8 million for the quarter.
• Free cash flow was approximately negative $15.7 million for the quarter.

Risks

• Continued depressed academic funding environment.
• Competitive activity in the proteomic insights space.
• Potential risks and uncertainties described in Seer's SEC filings.

Future Outlook

Seer continues to expect full year 2026 revenue to be in the range of $16 million to $18 million, representing growth of 3% at the midpoint over full year 2025.

Management Comments

• "Seer executed on several important drivers to advance the long-term trajectory of the business by generating traction on large-scale contracts with biobanks and supporting continued third-party validation of our platform," said Omid Farokhzad, Chair and Chief Executive Officer.
• "Seer sits at the forefront of deep, unbiased proteomics, a large and expanding market with profound scientific and commercial potential. We are building this market from the ground up, and the foundation we are laying is increasingly recognized by the world's leading scientists and institutions. We look forward to advancing our vision to empower the scientific community with unbiased proteomics solutions while creating value for all stakeholders."

Industry Context

StockSavvy.ai notes that Seer operates in the rapidly evolving field of proteomics, aiming to provide deep, unbiased insights. The company's results reflect challenges in academic funding and competitive pressures, common in emerging scientific technology sectors. The collaboration with Precision Health Research, Singapore, however, highlights the growing interest in large-scale population health studies utilizing advanced proteomic analysis.

Comparison to Industry Standards

• No direct comparisons to specific companies or industry benchmarks were provided in the filing for revenue, net loss, or operational efficiency.
• The doubling of independent publications to 84 year-over-year suggests an acceleration in third-party validation, which is a positive indicator in scientific research and development sectors.

Management Changes

Legal Proceedings

• Successfully defended and reinforced Seer's IP position through a U.S. Patent and Trademark Office Final Written Decision.

Related Party Transactions

• Service revenue included $56 thousand of related party revenue for the first quarter of 2026.

Stakeholder Impact

• Shareholders: Revenue decline may impact stock performance, but reaffirmation of guidance and strong cash position are mitigating factors. Share repurchases may benefit shareholders.
• Employees: Decrease in operating expenses driven by employee compensation may indicate cost management or restructuring efforts.
• Partners/Customers: Collaboration with Precision Health Research, Singapore indicates continued engagement with research institutions.
• Suppliers: Not explicitly mentioned.

Next Steps

• Continue to advance the vision to empower the scientific community with unbiased proteomics solutions.
• Focus on generating traction on large-scale contracts with biobanks.
• Support continued third-party validation of the platform.

Key Dates

Recommendation

The company reported a significant year-over-year revenue decline, which is a negative indicator. However, it reaffirmed its full-year guidance, possesses a substantial cash reserve ($220 million), and has made strategic advancements like a new collaboration and IP defense. The appointment of a new CCO also signals a focus on commercial growth. Given the mixed signals, a 'hold' recommendation is appropriate, pending further clarity on revenue trends and market adoption.

Keywords

proteomics, Seer, Inc., financial results, revenue, net loss, cash, guidance, Nasdaq: SEER